Intradermal, low dose, short course hepatitis B vaccination. 1986

P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt

Seventy-five of 88 (85.2%) vaccinees seroconverted at three months after three 2 micrograms doses of a plasma-derived hepatitis B vaccine had been given intradermally one month apart. Vaccinees under 30 years of age had a significantly better seroconversion rate (88.8%) than older subjects (50%) as measured at three months. Forty-three of 47 (91%) vaccinees who were bled one year post vaccination had antibody levels in excess of 10 IU/1. This study indicates that short course, low dose, intradermal vaccination with plasma-derived hepatitis B vaccine may be a viable and cheap regimen for inducing immunity against hepatitis B in younger subjects.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014761 Viral Hepatitis Vaccines Any vaccine raised against any virus or viral derivative that causes hepatitis. Hepatitis, Viral, Vaccines,Hepatitis Vaccines, Viral,Vaccines, Viral Hepatitis
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B

Related Publications

P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
January 1991, The Journal of the American Board of Family Practice,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
March 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
September 1988, Orvosi hetilap,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
February 1988, Vaccine,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
July 1986, JAMA,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
March 1993, The Medical journal of Australia,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
January 1997, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
June 1991, DICP : the annals of pharmacotherapy,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
January 1997, Revista do Instituto de Medicina Tropical de Sao Paulo,
P N Goldwater, and D G Woodfield, and A M Ramirez, and I S Anzimlt
January 1993, Scandinavian journal of infectious diseases,
Copied contents to your clipboard!